A placebo-controlled, double-blinded, randomized, trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Apocynin/paeonol (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors AKL Research and development; Nordic Bioscience
Most Recent Events
- 01 Jul 2024 Results published in the Osteoarthritis and Cartilage
- 04 Jun 2022 Primary endpoint WOMAC pain score has not been met, according to results presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism